What Chonluten is
Chonluten is a commercial name associated with the tripeptide EDG (Glu-Asp-Gly) and marketed for respiratory “bioregulation.” It has no FDA-approved product, respiratory indication, or dose.
Research does not establish a lung treatment
Published work has measured gene and protein expression in bronchial epithelial cultures and inflammatory responses in monocyte/macrophage cell systems.[1][2] These experiments do not show improved breathing, fewer exacerbations, infection treatment, fibrosis reversal, or clinical benefit in asthma or COPD.
Safety is unknown
No controlled human exposure program defines adverse events, pulmonary effects, immune reactions, interactions, pregnancy use, or long-term safety. Route and formulation cannot be inferred from cell-culture research.
Regulatory status
Chonluten is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no dose or administration protocol.